Core Viewpoint - The article discusses the recent developments regarding the GLP-1 drug semaglutide, particularly its second application for market approval in China aimed at long-term weight management for overweight and obese adults, alongside dietary control and increased physical activity [4][7]. Group 1: Company Developments - China National Pharmaceutical Group announced that its subsidiary, Shijiazhuang Pharmaceutical Group, has received acceptance for a second market application for semaglutide injection, targeting long-term weight management in overweight and obese adults [4]. - The first application for semaglutide was submitted in August, focusing on blood sugar control for adults with type 2 diabetes [4]. Group 2: Product Characteristics - Semaglutide is produced using a chemical synthesis process, classified as a chemical drug of category 2.2, indicating known active ingredients with improvements in formulation processes, providing clear clinical advantages [4]. - The product avoids impurities from host proteins during the fermentation process, achieving impurity levels comparable to those produced by recombinant technology [7]. Group 3: Clinical Efficacy - The mechanism of action involves binding to GLP-1 receptors, offering multiple clinical benefits such as weight loss, improved blood sugar levels, and cardiovascular and renal protection [7]. - Data from a phase III clinical study indicates that the drug significantly reduces weight and waist circumference in non-diabetic obese adults while also improving blood sugar, blood lipids, and liver enzyme levels [7]. - The overall efficacy and safety profile of semaglutide is highly consistent with that of Novo Nordisk's semaglutide, with slightly fewer adverse events reported [7].
速递｜石药集团：司美格鲁肽减重适应症申报上市！